NYSEAMERICAN:SYN - Synthetic Biologics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.6227 -0.02 (-3.11 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$0.6227
Today's Range$0.62 - $0.64
52-Week Range$0.51 - $15.75
Volume70,177 shs
Average Volume207,675 shs
Market Capitalization$8.40 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Synthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, overgrowth of pathogenic organisms, and the emergence of antimicrobial resistance; and SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The company's preclinical products include an oral formulation of the enzyme intestinal alkaline phosphatase to treat local GI disorders and systemic diseases; monoclonal antibody therapies for the prevention and treatment of pertussis; and novel discovery stage biotherapeutics for the treatment of phenylketonuria. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.

Receive SYN News and Ratings via Email

Sign-up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:SYN
CUSIPN/A
Phone+1-734-3327800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees24
Market Cap$8.40 million
OptionableNot Optionable

Synthetic Biologics (NYSEAMERICAN:SYN) Frequently Asked Questions

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN."

When did Synthetic Biologics' stock split? How did Synthetic Biologics' stock split work?

Shares of Synthetic Biologics reverse split before market open on Monday, August 13th 2018. The 1-35 reverse split was announced on Wednesday, August 1st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 10th 2018. An investor that had 100 shares of Synthetic Biologics stock prior to the reverse split would have 3 shares after the split.

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics Inc (NYSEAMERICAN:SYN) released its quarterly earnings results on Wednesday, August, 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.40) by $0.35. View Synthetic Biologics' Earnings History.

When is Synthetic Biologics' next earnings date?

Synthetic Biologics is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Synthetic Biologics.

What price target have analysts set for SYN?

2 equities research analysts have issued 12-month price objectives for Synthetic Biologics' shares. Their predictions range from $6.00 to $6.00. On average, they anticipate Synthetic Biologics' stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 863.5% from the stock's current price. View Analyst Price Targets for Synthetic Biologics.

What is the consensus analysts' recommendation for Synthetic Biologics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthetic Biologics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Synthetic Biologics.

What are Wall Street analysts saying about Synthetic Biologics stock?

Here are some recent quotes from research analysts about Synthetic Biologics stock:
  • 1. According to Zacks Investment Research, "Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered in Ann Arbor, Michigan. " (1/30/2019)
  • 2. HC Wainwright analysts commented, "We are lowering our price target to $6, from $38, as a result of pushing back timelines, a possible smaller indication for ribaxamase at launch, and increased share count due to capital raises. We base our $6 price target on probability-adjusted revenue forecasts for ribaxamase in the prevention of CDI and SYN-010 for the treatment of IBS-C. We use the net present value of our revenue forecast through 2028, apply a 35% probability of success (POS) for ribaxamase in CDI, a 25% POS for the early stage pipeline, and a 3x price/sales multiple to arrive at our price target." (11/20/2018)

Has Synthetic Biologics been receiving favorable news coverage?

Press coverage about SYN stock has been trending somewhat negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Synthetic Biologics earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days.

Are investors shorting Synthetic Biologics?

Synthetic Biologics saw a increase in short interest in January. As of January 15th, there was short interest totalling 435,038 shares, an increase of 8.2% from the December 31st total of 402,099 shares. Based on an average daily trading volume, of 160,767 shares, the days-to-cover ratio is presently 2.7 days. Currently, 3.4% of the shares of the company are short sold. View Synthetic Biologics' Current Options Chain.

Who are some of Synthetic Biologics' key competitors?

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the folowing people:
  • Mr. Steven A. Shallcross CPA, CEO, CFO, Treasurer, Corp. Sec. & Director (Age 58)
  • Vincent I. Perrone, Director of Corp. Communication
  • Dr. Michael Kaleko, Sr. VP of R&D
  • Dr. Raymond D. Stapleton Jr., Ph.D., Sr. VP of Manufacturing
  • Ms. Lara M. Guzman, Sr. Director of Project Operations

How do I buy shares of Synthetic Biologics?

Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synthetic Biologics' stock price today?

One share of SYN stock can currently be purchased for approximately $0.6227.

How big of a company is Synthetic Biologics?

Synthetic Biologics has a market capitalization of $8.40 million. Synthetic Biologics employs 24 workers across the globe.

What is Synthetic Biologics' official website?

The official website for Synthetic Biologics is http://www.syntheticbiologics.com.

How can I contact Synthetic Biologics?

Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at +1-734-3327800.


MarketBeat Community Rating for Synthetic Biologics (NYSEAMERICAN SYN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  335 (Vote Outperform)
Underperform Votes:  246 (Vote Underperform)
Total Votes:  581
MarketBeat's community ratings are surveys of what our community members think about Synthetic Biologics and other stocks. Vote "Outperform" if you believe SYN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel